SILVER SPRING
Eylea HD dosing interval extended to 5 months
- Sponsor
- Regeneron Pharmaceuticals $REGN
- Drug
- Eylea HD · aflibercept
- Indication
- wet age-related macular degeneration and diabetic macular edema
FDA approved extended dosing intervals up to 5 months for Eylea HD (aflibercept) in wet age-related macular degeneration and diabetic macular edema.
What this means
Eylea HD is an eye injection that blocks abnormal blood vessel growth in wet macular degeneration and diabetic macular edema, helping prevent vision loss. The FDA now allows patients to receive the treatment every 5 months instead of more frequent doses after showing stable vision. This could mean fewer doctor visits for patients while maintaining the same vision protection, though individual response may vary.
Drug Watch — recent news on Eylea HD
- A decade leading retinal care, Eylea 8mg now lasts even longer and better, expert says - Korea Biomedical Review
- Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum - Yahoo Finance
- Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says - marketscreener.com
- EYP-1901 reduces treatment burden, matches aflibercept on BCVA in wet AMD | Eye Care Network - Modern Retina - Ophthalmology Times
- Aflibercept and faricimab restore endothelial barrier function in retinal disease to a similar extent in a preclinical study - Ophthalmology Times
Sponsor Watch — recent news on Regeneron Pharmaceuticals
- Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
- In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
- Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
- Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
- FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia